Summary
The effect of various antacids on the absorption of tolfenamic and mefenamic acids has been investigated in three separate crossover studies, each consisting of four phases. Single doses of magnesium hydroxide (85 mg, 425 mg and 1700 mg) or of water (150 ml) were given by mouth to 6 healthy volunteers immediately after tolfenamic acid 400 mg (Study 1), and, using an identical study design, after mefenamic acid 500 mg (Study 3). In Study 2 sodium bicarbonate 1 g, aluminium hydroxide 1 g, an antacid preparation containing both aluminium and magnesium hydroxides, or water alone were ingested with tolfenamic acid 400 mg. Plasma concentrations of tolfenamic and mefenamic acids and their cumulative excretion in urine were determined up to 24 h. Magnesium hydroxide greatly accelerated, in a dose-dependent manner the absorption of both tolfenamic and mefenamic acids. The peak times in plasma were shortened by about 1 h by 425 mg and 1700 mg magnesium hydroxide, and the peak plasma concentrations of both fenamates were elevated up to 3-fold. The area under the plasma concentration-time curve between 0 and 1 h of tolfenamic acid was increased up to 7-fold and that of mefenamic acid up to 3-fold. The total bioavailability of tolfenamic and mefenamic acids was only slightly increased. Aluminium hydroxide alone and in combination with magnesium hydroxide significantly retarded the absorption and lowered the peak plasma concentration of tolfenamic acid. Sodium bicarbonate had no significant effect on its absorption. The interaction with magnesium hydroxide leads to higher and earlier peak plasma concentrations of the fenamates. Aluminium hydroxide prevents this effect of magnesium hydroxide. If rapid onset of the analgesic effect of the fenamates is required, concomitant ingestion of the fenamates with an antacid containing magnesium but not aluminium hydroxide is recommended.
Similar content being viewed by others
References
Ambre JJ, Fischer LJ (1973) Effect of coadministration of aluminium and magnesium hydroxides on absorption of anticoagulants in man. Clin Pharmacol Ther 14: 231–237
Balali-Mood M, Critchley JAJH, Proudfoot AT, Prescott LF (1981) Mefenamic acid overdose. Lancet 1: 1354–1956
D'Arcy PF, McElnay JC (1987) Drug-antacid interactions: assessment of clinical importance. Drug Intell Clin Pharm 21: 607–617
Nimmo WS (1976) Drugs, diseases and altered gastric emptying. Clin Pharmacokinet 1: 189–203
Pentikäinen PJ, Neuvonen PJ, Backman C (1981) Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur J Clin Pharmacol 19: 359–365
Riegelman S, Collier P (1980) The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 8: 509–534
Thoma K, Lieb H (1983) Sorption von Arzneistoffen an Antazida und Adsorbentien und deren Einfluss auf die biologische Verfügbarkeit. Dtsch Apoth Z 123: 2309–2316
Tokola RA, Neuvonen PJ (1984) Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol 17: 67–75
Tuderman V, Klinge E, Krogerus VE, Reijonen M (1979) In vivo study of certain antacid suspensions commercially available in Finland. Acta Pharm Fenn 88: 63–72
Segre EJ, Sevelius H, Varady J (1974) Effects of antacids on naproxen absorption. N Engl J Med 291: 582–583
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Neuvonen, P.J., Kivistö, K.T. Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids. Eur J Clin Pharmacol 35, 495–501 (1988). https://doi.org/10.1007/BF00558244
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558244